Literature DB >> 14557976

Amprenavir resistance imparted by the I50V mutation in HIV-1 protease can be suppressed by the N88S mutation.

Eric Lam, Neil T Parkin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14557976     DOI： 10.1086/378894

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  4 in total

1.  Effect of natural polymorphisms in the HIV-1 CRF02_AG protease on protease inhibitor hypersusceptibility.

Authors:  André F A Santos; Denis M Tebit; Matthew S Lalonde; Ana B Abecasis; Annette Ratcliff; Ricardo J Camacho; Ricardo S Diaz; Ottmar Herchenröder; Marcelo A Soares; Eric J Arts
Journal:  Antimicrob Agents Chemother       Date:  2012-02-13       Impact factor: 5.191

2.  2019 update of the drug resistance mutations in HIV-1.

Authors:  Annemarie M Wensing; Vincent Calvez; Francesca Ceccherini-Silberstein; Charlotte Charpentier; Huldrych F Günthard; Roger Paredes; Robert W Shafer; Douglas D Richman
Journal:  Top Antivir Med       Date:  2019-09

3.  Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbones.

Authors:  S Weinheimer; L Discotto; J Friborg; H Yang; R Colonno
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

4.  The Geogenomic Mutational Atlas of Pathogens (GoMAP) web system.

Authors:  David P Sargeant; Michael W Hedden; Sandeep Deverasetty; Christy L Strong; Izua J Alaniz; Alexandria N Bartlett; Nicholas R Brandon; Steven B Brooks; Frederick A Brown; Flaviona Bufi; Monika Chakarova; Roxanne P David; Karlyn M Dobritch; Horacio P Guerra; Kelvy S Levit; Kiran R Mathew; Ray Matti; Dorothea Q Maza; Sabyasachy Mistry; Nemanja Novakovic; Austin Pomerantz; Timothy F Rafalski; Viraj Rathnayake; Noura Rezapour; Christian A Ross; Steve G Schooler; Sarah Songao; Sean L Tuggle; Helen J Wing; Sandy Yousif; Martin R Schiller
Journal:  PLoS One       Date:  2014-03-27       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.